These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 18375236)

  • 1. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH; Cheung BM; Tse HF
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
    Oberwittler H; Baccara-Dinet M
    Int J Clin Pract; 2006 Jun; 60(6):707-15. PubMed ID: 16805757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Jacobson TA
    Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of niacin or nicotinic acid].
    Santos RD
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():17-9. PubMed ID: 16400392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ask the doctor. I tried taking niacin to increase my HDL but didn't like the flushing it caused. A friend told me about no-flush niacin, which works like a charm. Why not tell your readers about it?
    Lee T
    Harv Heart Lett; 2010 Mar; 20(7):8. PubMed ID: 20586132
    [No Abstract]   [Full Text] [Related]  

  • 12. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Bays HE; Ballantyne C
    Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
    Olsson AG
    Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of aspirin on niacin-induced cutaneous reactions.
    Whelan AM; Price SO; Fowler SF; Hainer BL
    J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.